United Therapeutics Shares Soar 5.27% as Analysts Hike Targets Despite 306th Market Activity Rank

On September 5, 2025, , , , ranking 306th in market activity. The stock has drawn attention following a price target upgrade by H.C. , . This adjustment followed positive trial data for Tyvaso in idiopathic pulmonary fibrosis (IPF), . , respectively, citing the drug’s efficacy in improving forced vital capacity () and secondary endpoints.

Analysts highlighted United Therapeutics’ strong operational metrics, , as supporting its valuation. The firm’s strategic expansion with to develop a second dry powder inhalation therapy further underscores its growth trajectory. However, risks remain, including potential underperformance of key products like Remodulin and Adcirca due to market dynamics or pricing pressures, as well as rising operating expenses without offsetting business development.

To run this back-test cleanly I need to pin down a few practical details: Universe—define whether to scan all U.S. equities or use a specific index. Execution convention—choose between trading at close-to-open or open-to-close. Rebalancing size—decide on equal-weighted entries. The default setup includes all NYSE and NASDAQ stocks, entry at next-day open, exit at close, no transaction costs, and a period from January 3, 2022, to September 4, 2025. Confirm if these parameters align with your requirements or adjustments needed before proceeding.